OTCMKTS:MYLGF - Mirati Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.07 0.00 (0.00 %)
(As of 05/27/2018 07:41 AM ET)
Previous Close$6.07
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average Volume355 shs
Market Capitalization$70.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Mirati Therapeutics (OTCMKTS:MYLGF)

MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.

Receive MYLGF News and Ratings via Email

Sign-up to receive the latest news and ratings for MYLGF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:MYLGF
CUSIPN/A
WebN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Mirati Therapeutics (OTCMKTS:MYLGF) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the OTCMKTS under the ticker symbol "MYLGF."

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Martin Godbout Ph.D, Chairman of the Board (Age 57)
  • Charles M. Baum M.D., Ph.D., President, Chief Executive Officer, Director (Age 55)
  • Mark J. Gergen, Chief Operations Officer, Executive Vice President (Age 51)
  • Rachel W. Humphrey M.D., Chief Medical Officer, Executive Vice President (Age 51)
  • Jamie A. Donadio, Vice President - Finance (Age 38)
  • Henry J. Fuchs M.D., Ph.D., Independent Director (Age 55)
  • Rodney W. Lappe Ph.D., Independent Director (Age 58)
  • Peter A. Thompson M.D., Independent Director (Age 53)

Has Mirati Therapeutics been receiving favorable news coverage?

News articles about MYLGF stock have trended positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mirati Therapeutics earned a news sentiment score of 0.42 on Accern's scale. They also gave media coverage about the company an impact score of 46.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Mirati Therapeutics?

Shares of MYLGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MYLGF stock can currently be purchased for approximately $6.07.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $70.20 million.


MarketBeat Community Rating for Mirati Therapeutics (MYLGF)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MYLGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYLGF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mirati Therapeutics (OTCMKTS:MYLGF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/27/2016 forward)

Earnings

Dividends

Mirati Therapeutics (OTCMKTS:MYLGF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mirati Therapeutics (OTCMKTS MYLGF) Insider Trading and Institutional Ownership History

Insider Trading History for Mirati Therapeutics (OTCMKTS:MYLGF)

Mirati Therapeutics (OTCMKTS MYLGF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Mirati Therapeutics (OTCMKTS MYLGF) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Mirati Therapeutics (OTCMKTS:MYLGF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Mirati Therapeutics (OTCMKTS MYLGF) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.